Last reviewed · How we verify

NCT06379529

The COPD CARE Study: Evaluating the Impact of a Virtual-First COPD Service on Major Cardiac and Respiratory Events

Not yet recruiting NA Last updated 28 May 2025
What this trial tests

NA trial testing NuvoAir clinical service in COPD Exacerbation in 1,050 participants. Not yet recruiting.

Timeline
1 January 2026
Primary endpoint
1 January 2027
1 December 2027

Quick facts

Lead sponsorNuvoAir Medical PC
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposesupportive care
Enrollment1,050
Start date1 January 2026
Primary completion1 January 2027
Estimated completion1 December 2027

Drugs / interventions tested

Conditions studied

Sponsor

NuvoAir Medical PC

Who can join

Adults 30 to 100, any sex, with COPD Exacerbation or COPD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A 12 month interventional study of up to 1,050 people with COPD to determine if the NuvoAir virtual-first clinical service leads to fewer moderate and severe COPD exacerbations and cardiac events, reduces healthcare utilization, and lowers the total cost of care compared to a control cohort that receives standard care only.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for COPD Exacerbation

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06379529.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing